Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Monday.

Oramed Pharmaceuticals Price Performance

Oramed Pharmaceuticals stock opened at $2.36 on Monday. The stock has a market cap of $95.14 million, a price-to-earnings ratio of 21.45 and a beta of 1.67. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67. The business’s 50-day simple moving average is $2.38 and its 200 day simple moving average is $2.41.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Marquette Asset Management LLC acquired a new position in Oramed Pharmaceuticals in the fourth quarter valued at approximately $81,000. XTX Topco Ltd raised its position in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,242 shares during the last quarter. Murchinson Ltd. boosted its position in shares of Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Oramed Pharmaceuticals in the 3rd quarter worth $272,000. Finally, BML Capital Management LLC grew its stake in shares of Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after purchasing an additional 837,153 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.